Scope, Claims, and US Patent Landscape for US Drug Patent 7,687,052
What is US 7,687,052 actually claiming?
US Patent 7,687,052 claims a narrow class of radiolabeled small-molecule compounds defined by a shared core “compound formula” with variable substituents Ra, Rb, Z, and q, plus a diagnostic composition and an in vivo imaging method for detecting amyloid deposits.
From the claims provided, the independent claim is Claim 1, and all other claims depend on it, meaning the patent’s enforceable scope is centered on the compound structure definition in Claim 1.
What is the scope of Claim 1 (core compound claim)?
Claim 1 covers:
1) A compound having the formula (structural placeholder in the text you provided), where:
- Ra and Rb are independently hydrogen or C1-4 alkyl
- Z is selected from: I, 123I, 125I, 131I, Br, 76Br, 77Br, F, 18F, or —OTosyl
- q is an integer from 2 to 5
Practical claim “degrees of freedom”
| Variable |
Allowed values (per Claim 1) |
Functional impact |
| Ra |
H or C1-4 alkyl |
Substitution pattern tuning while maintaining core scaffold |
| Rb |
H or C1-4 alkyl |
Same as Ra |
| Z (radio/leave group) |
I / 123I / 125I / 131I / Br / 76Br / 77Br / F / 18F / —OTosyl |
Drives the imaging label type and chemistry (including tosyl as a leaving group) |
| q |
2, 3, 4, 5 |
Alters substitution count/geometry in the scaffold |
What Claim 1 does not do
Based on the claim language you supplied, Claim 1:
- Does not broadly cover “any amyloid imaging radiotracer.” It is limited to compounds matching the defined formula and variable ranges.
- Does not expressly cover non-radiolabeled analogs, unless Z includes a non-radio leaving group that can be radiolabeled through a method not claimed here.
- Does not specify a particular imaging modality beyond using a radiolabeled compound for detection of amyloid deposits.
How do dependent claims narrow the structure set?
How do Claims 2, 9 narrow q and alkyl substitution?
- Claim 2: q is 3 or 4
- Claim 9: Ra and Rb are independently H or methyl, and q = 5
This creates three nested subspaces:
- Claim 1 baseline: q = 2–5, Ra/Rb each = H or any C1-4 alkyl
- Claim 2: restricts q to 3–4
- Claim 9: restricts Ra/Rb to H or methyl only, while forcing q = 5
How do Claims 3 through 8 narrow Ra/Rb and specific formulas?
- Claim 3: Ra = methyl, Rb = hydrogen
- Claims 4–8: each recites a specific formula (the text you provided shows “compound of claim 4 having the formula,” etc., but the actual formulas are not visible)
Operationally, Claims 4–8 are structure-specific fallbacks that carve out additional “species” within Claim 1. Because the specific substituent patterns for Claims 4–8 are not present in your excerpt, only the dependency structure is certain: they are narrower embodiments that further define the scaffold beyond the general variable ranges in Claim 1.
What is the scope of Claim 10 (diagnostic composition)?
Claim 10 covers:
- A diagnostic composition for imaging amyloid deposits, comprising a radiolabeled compound of Claim 1.
This is a classic “composition of matter” wrapper claim limited to:
- the diagnostic context (imaging amyloid deposits), and
- inclusion of a radiolabeled compound that itself must fall inside Claim 1.
What it likely covers in practice
The claim is not limited to any particular excipient list in your excerpt, but the definition requires a composition that includes the radiolabeled Claim 1 compound and is intended for amyloid imaging.
What is the scope of Claim 11 (method of imaging)?
Claim 11 covers an in vivo method:
1) Introduce into a mammal a detectable quantity of the diagnostic composition of Claim 10
2) Allow sufficient time for the labeled compound to associate with amyloid deposits
3) Detect the labeling compound associated with one or more amyloid deposits
This is a use claim tied to:
- a specific compound class (through Claim 10), and
- the imaging objective (amyloid deposits).
Key enforceability implications
- A method that uses a Claim 1-matching radiotracer in mammalian imaging steps can fall within Claim 11 even if the exact formulation differs, so long as the method uses a composition meeting Claim 10.
- If a competitor uses a non-Claim 1 radiotracer, the method claim typically fails at the “labeled compound of claim 1” requirement.
How does this patent fit the amyloid imaging radiotracer landscape?
The claim set is consistent with the broader market of amyloid PET/SPECT tracers that:
- use halogen radioisotopes (notably 18F and iodine isotopes), and
- bind amyloid plaques through a defined scaffold.
Your Claim 1 explicitly includes:
- 18F and F
- I and iodine isotopes (123I, 125I, 131I)
- Br and bromine radioisotopes (76Br, 77Br)
- and a chemical handle —OTosyl.
That combination maps onto a landscape where:
- many competitors design scaffolds with a radiohalogen substitution site, and
- the core dispute typically becomes whether the competitor’s tracer matches the structural boundaries of the Claim 1 formula, including the allowed substitution patterns and q range.
Where competition tends to cluster
Even without listing specific competitor patents here (the excerpt does not provide the written description, specification, priority claims, or actual compound examples), the claim architecture indicates the patent is intended to protect:
- radiolabeled species (multiple isotopes),
- narrow variants (q = 3–4; q = 5 and Ra/Rb constrained to H/methyl),
- and the imaging use.
That means the most direct competitive risks are:
1) radiotracers whose substitution pattern and radiolabeling site map into the Claim 1 variable grid, and
2) imaging kits or radiopharmaceutical products that include such tracers, and
3) PET/SPECT workflows that use those compositions for amyloid plaque detection.
Claim scope vs. “design-around” surface area
The claim variables define the surface area competitors can exploit:
Z (radio label / leaving group) is broad, not narrow
Claim 1 allows many radionuclides and halogen types:
- iodine, bromine, and fluorine (including 18F)
- plus —OTosyl
This breadth reduces the value of “changing the radioisotope” as a design-around. Many competitors instead need to change the scaffold or the substitution count and positions that are controlled by q and Ra/Rb.
q (2–5) is a meaningful narrowing knob
Because q is limited to 2–5, a competitor could attempt to change the scaffold to make it incompatible with q’s range. If q is tied to substitution number, geometry, or ring substitution count, that becomes a structural tripwire.
Ra/Rb (H or C1-4 alkyl) matters for minor substitutions
Allowing C1–4 alkyl means:
- small methyl/ethyl/propyl/butyl variants remain covered (subject to the actual formula definition).
Claim 9 narrows Ra/Rb to H or methyl with q = 5, but Claim 1 already covers more alkyl types.
What would infringement analysis hinge on?
For Claim 1 and derivatives (Claims 2–9), the pivotal fact pattern is:
1) Does the competitor’s tracer match the exact scaffold of the Claim 1 “formula” (not visible in your excerpt), and
2) do its substituents satisfy:
- Ra/Rb each = H or C1-4 alkyl
- q within 2–5
- Z equal to one of the listed radio/halogen/OTosyl options
For Claim 10, infringement requires:
- use of a Claim 1-matching radiolabeled compound in a diagnostic formulation for amyloid imaging.
For Claim 11, infringement requires:
- use of a Claim 10 composition and the method steps for imaging amyloid deposits in a mammal.
What is missing from the excerpt that limits landscape mapping?
A complete “patent landscape” requires at minimum:
- priority date(s),
- inventor/applicant,
- claim construction details from the written description,
- the explicit formula images for Claims 4–8,
- prosecution history and cited art,
- expiration status and any terminal disclaimers,
- any related continuations/divisionals.
Your provided text includes only the claim excerpts and not the patent bibliographic data or the missing structural formulas. Without those, the landscape cannot be reliably mapped to specific overlapping patents, assignees, or competing tracer families.
Per the constraint, this analysis therefore stays at the level of claim-defined scope and direct competitive implication, not an enumerated citation network.
Key Takeaways
- US 7,687,052’s core protection is Claim 1’s defined compound class, with variability in Ra/Rb (H or C1-4 alkyl), Z (iodine/bromine/fluorine radios and —OTosyl), and q (2–5).
- Dependent claims tighten scope via q restrictions (q = 3–4 in Claim 2; q = 5 with Ra/Rb restricted to H or methyl in Claim 9) and specific substitution embodiments (Claim 3, and Claims 4–8 as additional species).
- The patent extends from compounds into use and product form through:
- Claim 10: diagnostic composition for amyloid imaging containing a Claim 1 radiolabeled compound.
- Claim 11: method of imaging amyloid deposits in a mammal using that composition and detecting plaque-associated signal.
- Changing radionuclide alone is unlikely to avoid coverage because Z allows multiple iodine and halogen options including 18F; design-around likely requires scaffold or substitution pattern changes that escape the Claim 1 formula constraints, especially around q and the scaffold-defined positions for Ra/Rb and the Z site.
FAQs
1) Is US 7,687,052 limited to PET tracers?
No. Claim 1 explicitly includes 18F and also iodine and bromine isotopes, which can support PET and SPECT depending on isotope selection and formulation.
2) Does Claim 10 cover any diagnostic kit for Alzheimer’s?
No. Claim 10 is limited to a diagnostic composition for imaging amyloid deposits that includes a radiolabeled compound of Claim 1.
3) Can a competitor avoid infringement by using a different radioisotope?
Not by changing only the radioisotope type. Claim 1 allows multiple iodine, bromine, and fluorine options, so the compound must still match the Claim 1 scaffold and variable constraints.
4) Which claim is the main driver of scope?
Claim 1. All other compound claims depend on Claim 1, and both the composition (Claim 10) and method (Claim 11) depend on it through the requirement to use a Claim 1 radiolabeled compound.
5) What structural parameter is a likely design-around lever?
q. Claim 1 restricts q to 2–5, and dependent claims further restrict to 3–4 or q = 5 with tighter Ra/Rb limits in Claim 9.
References
[1] US Patent 7,687,052. Claims as provided in user excerpt (Claims 1–11).
